Latest ArticlesTo compare the thrombolytic efficacy and safety of tenecteplase and alteplase in the treatment of acute posterior circulation infarction(APCI).
A total of 90 patients with APCI admitted to second people's hospital of Mengcheng county from January 2023 to December 2024 were selected as research subjects and randomly divided into the tenecteplase group and the alteplase group, with 45 cases in each group. Both groups received 14 days of treatment. The vascular recanalization rate, levels of neuron-specific enolase(NSE), S100 calcium-binding protein B(S100-β) and 5-hydroxytryptamine(5-HT), National Institutes of Health Stroke Scale(NIHSS) scores, 90-day prognosis and incidence of hemorrhage were compared between the two groups.
After treatment, the vascular recanalization rate of the tenecteplase group was higher than that of the alteplase group(60.00% vs. 46.67%), but no significant difference was observed(P>0.05). The levels of NSE and S100-β in the tenecteplase group were lower than those in the alteplase group, while the 5-HT level was higher than that in the alteplase group(P<0.05). The NIHSS scores of the tenecteplase group at 7 days and 14 days after treatment were both lower than those of the alteplase group(P<0.05). The proportion of patients with favorable 90-day prognosis of the tenecteplase group was higher than that of the alteplase group(73.33% vs. 53.33%, P<0.05). There was no statistically significant difference in the total incidence of hemorrhage between the two groups(P>0.05).
In intravenous thrombolysis of APCI, there is no significant difference in the incidence of favorable neurological functional outcomes at 90 days after treatment between tenecteplase and alteplase. Tenecteplase has a higher early vascular recanalization rate than alteplase, which can effectively promote the blood flow restoration of ischemic brain tissue and facilitate the repair of neurological function. The overall safety profiles of the two agents are comparable.
To investigate the therapeutic effect and safety of Gushen Yizhi decoction on vascular Parkinsonism(VP) patients with liver-kidney Yin deficiency syndrome.
A total of 90 VP patients with live-kidney Yin deficiency admitted to Fu'nan county hospital from January 2024 to June 2025 were selected as research subjects, and randomly divided into the control group and the observation group, with 45 cases in each group. The control group was treated with levodopa and benserazide hydrochloride, while the observation group received additional Gushen Yizhi decoction on the basis of the control group. Both groups underwent 2 weeks of continuous treatment. The clinical efficacy was compared between the two groups. The levels of nerve growth factor(NGF) and brain-derived neurotrophic factor(BDNF) were detected and compared. Hemorheological parameters including high shear whole blood viscosity(HS), low shear whole blood viscosity(LS), plasma viscosity(PV) and platelet aggregation rate (PAR) were evaluated. The scores of the unified Parkinson disease rating scale(UPDRS) and the incidence of complications were also compared between the two groups.
After treatment, the total clinical effective rate of the observation group was significantly higher than that of the control group(93.33% vs. 75.56%, P<0.05). After intervention, the levels of NGF and BDNF in both groups were elevated compared with before treatment, and the observation group presented significantly higher levels than the control group(P<0.05). The levels of HS, LS, PV, PAR and all dimensions of UPDRS scores in both groups decreased notably after treatment, and these indicators in the observation group were significantly lower than those in the control group(P<0.05). No statistically significant difference in the incidence of complications between the two groups(P>0.05).
For VP patients with liver-kidney Yin deficiency syndrome, Gushen Yizhi decoction can effectively improve the clinical therapeutic effect, further ameliorate clinical symptoms and blood circulation status, and possesses favorable safety profile.
To compare the anticoagulant effects of nafamostat mesylate and nadroparin calcium in continuous renal replacement therapy(CRRT) for patients with acute kidney injury(AKI).
The clinical data of 90 AKI patients from our hospital from August 2023 to December 2024 were retrospectively analyzed. According to the different anticoagulants used in CRRT treatment, the patients were divided into group A(nafamostat mesylate anticoagulation, 47 cases) and group B(nadroparin calcium anticoagulation, 43 cases). The anticoagulant effects, pre- and post-treatment coagulation factors[activated partial thromboplastin time(APTT), fibrinogen(FIB), D-dimer(D-D)], renal function indicators[uric acid(UA), cystatin(Cys)C, blood urea nitrogen(BUN), creatinine clearance rate(CCR)], filter usage time, and adverse reactions were compared between the two groups.
The anticoagulation efficacy of group A was higher than that of group B(P<0.05), and the filter usage time was longer than that of group B(P<0.05). After treatment, the FIB, D-D, and CCR in both groups increased compared with those before treatment(P<0.05), while APTT, CysC, BUN, and UA decreased compared with those before treatment(P<0.05), and group A was better than group B(P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups(P>0.05).
For AKI patients undergoing CRRT treatment, the anticoagulant effect of nafamostat mesylate is superior to that of nadroparin calcium, which is beneficial for improving renal function, reducing the levels of inflammatory factors, improving coagulation function, and is safe.
To compare the clinical effect of tegoprazan and esomeprazole in the treatment of reflux esophagitis(RE).
A total of 160 patients with RE admitted to our hospital from August 2023 to January 2025 were selected as research subjects and randomly divided into the study group and the control group, with 80 cases in each group. The study group was treated with tegoprazan, while the control group was treated with esomeprazole. Both groups received continuous treatment for 8 weeks. After treatment, the clinical efficacy of the two groups was evaluated.The scores of Reflux Disease Questionnaire(RDQ) and Gastroesophageal Reflux Disease Questionnaire(GERDQ), the changes in the levels of gastrointestinal hormones, inflammatory factors and oxidative stress indicators before and after treatment were compared between the two groups.
The total effective rate of the study group was higher than that of the control group(93.75% vs. 82.50%, P<0.05). After treatment, the RDQ and GERDQ scores of both groups decreased compared with those before treatment, and the scores of the study group were lower than those of the control group(all P<0.05). The levels of gastrin, motilin and superoxide dismutase in both groups increased compared with those before treatment, and the levels in the study group were higher than those in the control group(P<0.05). The levels of vasoactive intestinal peptide, cholecystokinin, high-sensitivity C-reactive protein, interleukin-6, malondialdehyde and inducible nitric oxide synthase in both groups decreased compared with those before treatment, and the levels in the study group were lower than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).
Compared with esomeprazole, tegoprazan can effectively improve the therapeutic effect in RE patients. It has additional effects in regulating gastrointestinal hormone levels, relieving inflammatory response and oxidative stress response, and the safety profiles of the two drugs are comparable.
To explore the effects of different doses of dexmedetomidine on postoperative delirium(POD)and inflammatory cytokine levels in elderly patients undergoing elective lumbar spinal stenosis(LSS) surgery.
A total of 90 eligible LSS patients who received surgical intervention in the Department of Spinal Surgery in our hospital from January 2024 and June 2025 were selected and randomly divided into three groups: the low-dose group(intraoperative continuous dexmedetomidine infusion at 0.2 μg·kg-1·h-1), the high-dose group(intraoperative continuous dexmedetomidine infusion at 0.5 μg·kg-1·h-1), and the control group(intraoperative continuous normal saline infusion), with 30 cases in each group. Serial assessments were performed at four predefined time points: pre-operation(T0), 1 hour after anesthesia emergence(T1), postoperative day 1(T2) and postoperative day 3(T3). The Mini-Mental State Examination(MMSE)scores, and the levels of interleukin(IL)-6, IL-10 and tumor necrosis factor(TNF)-α were recorded.
At T3, the incidence of POD in the low-dose, high-dose and control groups was 6.67%, 13.33% and 26.67%, respectively. The difference between the low-dose group and the control group was statistically significant(P<0.05). In terms of the POD duration, the duration in the low-dose group, high-dose group and control group was 72.32(64.82, 81.19)h, 93.55(82.98, 108.99)h and 97.57(86.87, 115.23)h, respectively. The POD duration in the low-dose group was significantly shorter than those in the other two groups. In terms of MMSE scores, there were no significant differences among the three groups at T0 and T3(P>0.05). At T1, the MMSE scores of the low-dose group and the control group were both significantly higher than that of the high-dose group(P<0.05). At T2, the MMSE score in the low-dose group was significantly higher than those in the other two groups(P<0.05). From T1 to T3, the levels of IL-6 and TNF-α in the high-dose group were significantly lower than those in the control group(P<0.001), and the level of IL-10 was significantly higher(P<0.001).Correlation analysis revealed that POD was significantly positively correlated with IL-6 and TNF-α levels at T3 point, and significantly negatively correlated with IL-10 level at T3 point.
For elderly patients undergoing LSS surgery, perioperative administration of low-dose dexmedetomidine can substantially reduce POD incidence and shorten POD duration without compromising postoperative emergence quality. The underlying mechanism may be closely related to inhibiting the massive release of IL-6 and TNF-α, and upregulating the anti-inflammatory cytokine IL-10.
Oritavancin is a novel antimicrobial agents with broad-spectrum antibacterial activity against multi-drug resistant bacteria, particularly showing excellent activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant strains. Oritavancin is mainly used to treat acute bacterial skin and skin structure infections caused by Gram-positive bacteria and offers the advantage of convenient administration. This article mainly reviewed the clinical studies and related aspects of oritavancin, in order to provide reference for its clinical application.
Nephrotic syndrome(NS) is a group of clinical syndromes characterized by massive proteinuria, hypoproteinemia, edema and hyperlipidemia. At present, its clinical treatment still faces prominent challenges including limited remission rate, high recurrence rate and adverse reaction of long-term medication. In recent years, novel small-molecule inhibitors targeting B cells and inflammatory signaling pathways, such as Bruton's tyrosine kinase inhibitors, spleen tyrosine kinase inhibitors and Janus kinase inhibitors, have become a key research direction in the field of kidney disease treatment, dues to their advantages of high target specificity and convenient administration. This paper systematically reviewed the mechanisms of action, preclinical and clinical research progress of the above three categories of inhibitors, discussed their application value and existing challenges in NS treatment, so as to provide references for clinical practice.
Steroid-resistant nephrotic syndrome(SRNS) in children is one of the most challenging disease entities in the field of pediatric nephrology, with a high long-term risk of progressing to end-stage renal disease. Calcineurin inhibitors, mainly including tacrolimus and cyclosporine A, are currently the first-line immunosuppressive agents for the treatment of non-genetic(idiopathic) childhood SRNS. This paper systematically reviewed the efficacy differences of calcineurin inhibitors in different types of childhood SRNS, as well as their core role in combination and sequential therapy. It also discussed the application status of these agents in economically underdeveloped areas and the future research directions, to provide references for further optimizing the individualized treatment strategies for childhood SRNS.
To explore the chondroprotective effect of chlorogenic acid on rats with knee osteoarthritis(KOA) and its underlying mechanism.
A KOA rat model was established and randomly divided into the blank group, the model group, the high-dose chlorogenic acid group(20 mg/kg), the low-dose chlorogenic acid group(10 mg/kg), and the positive control group(dipivefrin 50 mg/kg). The knee joint functions and the severity of cartilage lesions among different groups, the levels of serum tumor necrosis factor(TNF)-α, interleukin(IL)-1β, the levels of matrix metalloproteinase (MMP)-13 in synovial fluid, disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-5 in synovial fluid, and the gene and protein expressions of factors related to the cartilage Toll-like receptor(TLR) 4/nuclear factor(NF)-κB signaling pathway were compared.
Compared with the model group, the chlorogenic acid group showed a significantly reduced Lequesne MG score for knee joint function(P<0.05), significantly lower Mankin's score for joint cartilage lesions(P<0.01), significantly decreased serum TNF-α and IL-1β and the levels of MMP-13 and ADAMTS-5 in synovial fluid (P<0.01), and significantly downregulated the gene expressions of TLR4, MyD88, and NF-κB p65 in knee joint cartilage and the relative expressions of TLR4/β-actin, MyD88/β-actin, and p-NF-κB p65/NF-κB p65 proteins(P<0.01). The improvement in the high-dose chlorogenic acid group was better than that in the low-dose chlorogenic acid group, and there was a dose-dependent trend.
Chlorogenic acid can effectively improve the knee joint function and protect the articular cartilage of KOA rats, which may be related to its inhibition of the TLR4/NF-κB signaling pathway and thereby downregulating the expression of inflammatory factors and matrix-degrading enzymes.